Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 1.06
STEM's Cash to Debt is ranked lower than
79% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 60.34 vs. STEM: 1.06 )
Ranked among companies with meaningful Cash to Debt only.
STEM' s 10-Year Cash to Debt Range
Min: 0.66  Med: 5.10 Max: 63.74
Current: 1.06
0.66
63.74
Equity to Asset -0.11
STEM's Equity to Asset is ranked lower than
94% of the 594 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. STEM: -0.11 )
Ranked among companies with meaningful Equity to Asset only.
STEM' s 10-Year Equity to Asset Range
Min: -0.11  Med: 0.60 Max: 0.83
Current: -0.11
-0.11
0.83
F-Score: 5
Z-Score: -31.59
M-Score: -2.28
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -4750.72
STEM's Operating margin (%) is ranked lower than
88% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -71.01 vs. STEM: -4750.72 )
Ranked among companies with meaningful Operating margin (%) only.
STEM' s 10-Year Operating margin (%) Range
Min: -50159.65  Med: -2709.38 Max: -63.56
Current: -4750.72
-50159.65
-63.56
Net-margin (%) -4967.15
STEM's Net-margin (%) is ranked lower than
89% of the 657 Companies
in the Global Biotechnology industry.

( Industry Median: -69.93 vs. STEM: -4967.15 )
Ranked among companies with meaningful Net-margin (%) only.
STEM' s 10-Year Net-margin (%) Range
Min: -43900  Med: -2609.62 Max: -75.42
Current: -4967.15
-43900
-75.42
ROE (%) -706.83
STEM's ROE (%) is ranked lower than
97% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -30.92 vs. STEM: -706.83 )
Ranked among companies with meaningful ROE (%) only.
STEM' s 10-Year ROE (%) Range
Min: -314.44  Med: -102.02 Max: -19.04
Current: -706.83
-314.44
-19.04
ROA (%) -106.63
STEM's ROA (%) is ranked lower than
86% of the 848 Companies
in the Global Biotechnology industry.

( Industry Median: -26.61 vs. STEM: -106.63 )
Ranked among companies with meaningful ROA (%) only.
STEM' s 10-Year ROA (%) Range
Min: -102.9  Med: -58.49 Max: -13.62
Current: -106.63
-102.9
-13.62
ROC (Joel Greenblatt) (%) -635.23
STEM's ROC (Joel Greenblatt) (%) is ranked lower than
55% of the 819 Companies
in the Global Biotechnology industry.

( Industry Median: -356.32 vs. STEM: -635.23 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
STEM' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -1658.37  Med: -488.68 Max: -60.94
Current: -635.23
-1658.37
-60.94
Revenue Growth (3Y)(%) -39.40
STEM's Revenue Growth (3Y)(%) is ranked lower than
80% of the 402 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. STEM: -39.40 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
STEM' s 10-Year Revenue Growth (3Y)(%) Range
Min: -100  Med: -30.70 Max: 128.9
Current: -39.4
-100
128.9
EBITDA Growth (3Y)(%) -30.20
STEM's EBITDA Growth (3Y)(%) is ranked lower than
81% of the 427 Companies
in the Global Biotechnology industry.

( Industry Median: -3.90 vs. STEM: -30.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
STEM' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -34.1  Med: -14.40 Max: 9.6
Current: -30.2
-34.1
9.6
EPS Growth (3Y)(%) -29.80
STEM's EPS Growth (3Y)(%) is ranked lower than
78% of the 413 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. STEM: -29.80 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
STEM' s 10-Year EPS Growth (3Y)(%) Range
Min: -33.6  Med: -17.40 Max: 24.1
Current: -29.8
-33.6
24.1
» STEM's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

STEM Guru Trades in

Q3 2014

STEM Guru Trades in Q3 2014

Jim Simons 60,633 sh (New)
» More
Q4 2014

STEM Guru Trades in Q4 2014

Jim Simons 48,199 sh (-20.51%)
» More
Q1 2015

STEM Guru Trades in Q1 2015

Jim Simons Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with STEM

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 34.80
STEM's P/S is ranked lower than
180% of the 591 Companies
in the Global Biotechnology industry.

( Industry Median: 11.51 vs. STEM: 34.80 )
Ranked among companies with meaningful P/S only.
STEM' s 10-Year P/S Range
Min: 0  Med: 149.00 Max: 3320
Current: 34.8
0
3320
Current Ratio 1.67
STEM's Current Ratio is ranked lower than
79% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.38 vs. STEM: 1.67 )
Ranked among companies with meaningful Current Ratio only.
STEM' s 10-Year Current Ratio Range
Min: 1.67  Med: 5.58 Max: 21.05
Current: 1.67
1.67
21.05
Quick Ratio 1.67
STEM's Quick Ratio is ranked lower than
74% of the 814 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. STEM: 1.67 )
Ranked among companies with meaningful Quick Ratio only.
STEM' s 10-Year Quick Ratio Range
Min: 1.67  Med: 5.58 Max: 21.05
Current: 1.67
1.67
21.05
Days Sales Outstanding 8.94
STEM's Days Sales Outstanding is ranked higher than
91% of the 557 Companies
in the Global Biotechnology industry.

( Industry Median: 61.10 vs. STEM: 8.94 )
Ranked among companies with meaningful Days Sales Outstanding only.
STEM' s 10-Year Days Sales Outstanding Range
Min: 2.27  Med: 46.58 Max: 8100.44
Current: 8.94
2.27
8100.44

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) (%) -58.78
STEM's Earnings Yield (Greenblatt) (%) is ranked lower than
93% of the 816 Companies
in the Global Biotechnology industry.

( Industry Median: -5.50 vs. STEM: -58.78 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
STEM' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -59.88  Med: 764.40 Max: 54835.9
Current: -58.78
-59.88
54835.9

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:CY9A.Germany,
StemCells Inc is a Delaware Corporation incorporated in 1988. The Company is engaged in the research, development, and commercialization of stem cell therapeutics and related enabling technologies for academia and industry. It is focused on cellular medicine, or the use of stem and progenitor cells as the basis for novel therapeutics and therapies, and enabling technologies for stem cell research, or the use of cells and related technologies to enable stem cell-based research and drug discovery and development. The Company's primary research and development efforts are focused on cellular medicine, where it seeks to identify and develop stem and progenitor cells as potential therapeutic agents. It currently has two therapeutic product development programs; its CNS Program, which is developing applications for HuCNS-SC cells, its proprietary human neural stem cell product candidate, and its Liver Program, which is developing applications for its proprietary human liver engrafting cells. It currently markets various proprietary cell culture products under the SC Proven brand, including iSTEM, GS1-R, GS2-M, RHB-A, RHB-Basal, NDiff227, NDiff N2, and NDiff N27. The Company's primary strategy is to identify multiple types of human stem and progenitor cells with therapeutic and commercial importance, to develop techniques and processes to purify these cells for direct transplant and to expand and bank these cells, to advance these cells into clinical development and ultimately, to commercialize them as cell-based therapeutic products. The Company's research and development activities and the future manufacturing and marketing of its potential therapeutic products are, and would continue to be, subject to regulation for safety and efficacy by numerous governmental authorities in the United States and other countries.
» More Articles for STEM

Headlines

Articles On GuruFocus.com
Billionaires Hold Waning Biotechs 42% Off Oct 16 2013 
comment on STEM Feb 09 2012 
Two Biotech Stocks to Buy, One to Avoid Jan 09 2012 
StemCells Inc. Reports Operating Results (10-Q) Nov 03 2010 
StemCells Inc. Reports Operating Results (10-Q) May 04 2010 
StemCells Inc. Reports Operating Results (10-Q) Nov 05 2009 
StemCells, Inc. Reports Second Quarter Financial Results Aug 10 2009 
StemCells Inc. Reports Operating Results (10-Q) Aug 10 2009 
The Next Boom Emerges Nov 23 2008 

More From Other Websites
StemCells, Inc. to Participate at Cantor Fitzgerald's Inaugural Healthcare Conference Jul 01 2015
StemCells, Inc. to Participate at Cantor Fitzgerald's Inaugural Healthcare Conference Jul 01 2015
STEMCELLS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 29 2015
StemCells, Inc.'s Phase II Pathway Study for Cervical Spinal Cord Injury Approved by Health Canada Jun 26 2015
StemCells, Inc. Reports Top Line Results for Its Phase I/II Study in Dry Age Related Macular... Jun 26 2015
StemCells, Inc. Reports Top Line Results for Its Phase I/II Study in Dry Age Related Macular... Jun 26 2015
Edited Transcript of STEM earnings conference call or presentation 5-May-15 8:30pm GMT Jun 22 2015
StemCells, Inc.'s Phase II Pathway Study for Cervical Spinal Cord Injury Approved by Health Canada Jun 18 2015
STEMCELLS INC Files SEC form 8-K, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year,... Jun 15 2015
STEMCELLS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Jun 05 2015
Will StemCells (STEM) Continue to Surge Higher? - Tale of the Tape Jun 04 2015
StemCells, Inc. Announces Commencement of the Second Cohort of the Pathway(TM) Study in Cervical... Jun 04 2015
StemCells, Inc. Announces Closing of Over-Allotment Option Jun 01 2015
StemCells, Inc. Announces Closing of Over-Allotment Option Jun 01 2015
StemCells (STEM) Worth Watching: Stock Rises 10.7% - Tale of the Tape May 26 2015
Coverage initiated on StemCells by Cantor Fitzgerald May 22 2015
StemCells, Inc. to Participate at the 2015 Marcum MicroCap Conference May 18 2015
StemCells, Inc. to Participate at the 2015 Marcum MicroCap Conference May 18 2015
STEMCELLS INC Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule... May 15 2015
STEMCELLS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits May 14 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK